peoplePerson
Thomas U. Marron
Showed that neoadjuvant immunotherapy can produce major pathologic responses in liver cancer.
Runs Mount Sinai's early-phase unit and led perioperative cemiplimab studies in hepatocellular carcinoma and window-of-opportunity trials.
Role
Director, Early Phase Trials Unit
Specialisms
Neoadjuvant immunotherapyLiver cancerPhase 1 trials
Profiles
| Title | Journal | Year |
|---|---|---|
| Neoadjuvant cemiplimab for resectable hepatocellular carcinoma: a single-arm, open-label, phase 2 trial | Lancet Gastroenterology & Hepatology | 2022 |
Pages like this
not linked directly; found by shared links- PersonMiriam Merad
Shares The Mount Sinai Hospital / Tisch Cancer Institute, Hepatocellular carcinoma.
- TermDownstaging and conversion therapy
Shares Neoadjuvant / adjuvant / perioperative, Hepatocellular carcinoma.
- Key paperNIAGARA: durvalumab before and after cystectomy for muscle-invasive bladder cancer
Shares The Mount Sinai Hospital / Tisch Cancer Institute, Neoadjuvant / adjuvant / perioperative.
- PathwayOncogenic viruses
Shares Cemiplimab, Hepatocellular carcinoma.